Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: A substudy of the ISS-PART trial

AIDS Research and Human Retroviruses

Volumn 26, Issue 5, 2010, Pages 541-545

  Pirillo, Maria ^a   Palmisano, Lucia ^a   Pellegrini, Manuela ^a   Galluzzo, Clementina ^a   Weimer, Liliana ^a   Bucciardini, Raffaella ^a   Fragola, Vincenzo ^a   Andreotti, Mauro ^a   Marchei, Emilia ^a   Pichini, Simona ^a   Vella, Stefano ^a   Giuliano, Marina ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INTERRUPTION; TREATMENT WITHDRAWAL; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952560260     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0116     Document Type: Article

References (16)

1. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ count guided interruption of antiretroviral treatment. N Engl J Med 2006;355;2359-2361.
2. The Italian Cohort of Antiretroviral-Näve Patients Study Group: Interruption of highly active antiretroviral therapy in HIV clinical practice. J Acquir Immune Defic Syndr 2005; 38:407-416.
3. The CASCADE Collaboration: Highly active antiretroviral therapy interruption: Predictors and virologic and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42:554-561.
4. Fox Z, Phillips A, Cohen C, et al.: Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitorbased regimen. AIDS 2008;22:2279-2289.
5. Danel C, Moh R, Chaix ML, et al.: Two-months-off, fourmonths- on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: A randomized trial involving West African adults. J Infect Dis 2009;199:66-76.
6. Palmisano L, Giuliano M, Bucciardini R, et al.: Determinants of virologic and immunologic outcomes in chronically HIVinfected subjects undergoing repeated treatment interruptions; The Istituto Superiore di Sanità -Pulsed Antiretroviral Therapy (ISS-PART) Study. J Acquir Immune Defic 2007;46: 39-47.
7. CPMP/ICH/281/95. EEC Note for Guidance, Validation of Analytical Procedures: Methodology. London, UK, 1996. http://www.emea.eu.int/htms/ human(ich/quality/ichfin .htm.
8. U.S. Department of Health and Human Services Food and Drug Administration: Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Beltsville, MD, 2001.
9. Marchei E, Farré M, Pellegrini M, et al.: Liquid chromatography- electrospray ionization mass spectrometry determination of methylphenidate and ritalinic acid in conventional and non-conventional biological matrices. J Pharm Biomed Anal 2009;49:434-439.
10. Taylor S, Boffito M, Khoo S, Smit E, and Back D: Stopping antiretroviral therapy. AIDS 2007;21:1673-1682.
11. Ribaudo HJ, Haas DW, Tierney C, et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42:401-407.
12. Mackie NE, Fidler S, Tamm N, et al.: Clinical implications of stopping nevirapine-based antiretroviral therapy: Relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004;5:180-184.
13. Cressey TR, Green H, Khoo S, et al.: Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008;46:1601-1608.
14. Kikaire B, Khoo S, Walker AS, et al.: Nevirapine clearance from plasma in African adults stopping therapy: A pharmacokinetic substudy. AIDS 2007;21:733-737.
15. Hare CB, Mellors J, Krambrink A, et al.: Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008;47:421-424.
16. Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, and Martinez-Picado J: Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008;13:945-951.